Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-030766
Filing Date
2024-08-08
Accepted
2024-08-08 16:07:53
Documents
60
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 752798
2 ex31-1.htm EX-31.1 18224
3 ex31-2.htm EX-31.2 18168
4 ex32-1.htm EX-32.1 7051
5 ex32-2.htm EX-32.2 4486
  Complete submission text file 0001493152-24-030766.txt   3799110

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20240630.xsd EX-101.SCH 29477
7 XBRL CALCULATION FILE ltrn-20240630_cal.xml EX-101.CAL 43851
8 XBRL DEFINITION FILE ltrn-20240630_def.xml EX-101.DEF 93199
9 XBRL LABEL FILE ltrn-20240630_lab.xml EX-101.LAB 242553
10 XBRL PRESENTATION FILE ltrn-20240630_pre.xml EX-101.PRE 191397
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 513377
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 241188296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)